Accelovance Continues Expansion with Opening of Research Triangle Park, NC Office
ROCKVILLE, MD, US - Feb 19, 2014 - Accelovance, a therapeutically focused clinical research organization (CRO), announced today the opening of a new office in Research Triangle Park (RTP), North Carolina. This office opening supports continued corporate expansion and provides Accelovance's clients and employees with a presence in the research-active landscape of the RTP area of North Carolina. The new offices are close to many current and potential clients and offer a rich base of technical talent to support continued corporate growth.
"Building and scaling a high-quality team is a key driver to our continued success as a business," said Stephen Trevisan, President and CEO. "RTP was one of our top choices as a location, since it offers an excellent talent pool of research professionals who have the experience to help us better serve our customers."
Accelovance plans to add up to 15 new clinical operations positions in the RTP area this year.
About Accelovance
Accelovance is an award-winning, niche CRO focused primarily in oncology, vaccines, and general medicine. Accelovance operates four core service divisions; a full-service Contract Research Organization, Site Management Organization, Patient Recruitment, and Call Center that positively impact the advancement of clinical research. As a clinical services provider to the pharmaceutical and biotech industries, Accelovance offers comprehensive services including management and implementation of Phase I-IV clinical trials, patient recruitment/retention solutions, and a Clinical Call Center that can assist in recruitment, retention, and post-marketing surveillance.
Accelovance is a privately held company headquartered in Rockville, Maryland, and has offices in Chicago, IL; Stuart, FL; and Beijing, China; as well as research sites in Rockville, MD; Melbourne, FL; Peoria, IL; Mishawaka, IN; Huntsville, AL; and San Diego, CA. Established in 2005 with a corporate mission to improve the quality and predictability in clinical research, Accelovance has made significant strides in the industry by combining strong business and operational perspective with clinical and medical expertise.
For more information, visit the company's Web site at www.accelovance.com.
# # #
Press Contact: Michael Keens, VP Business Development
240.238.4941
mkeens@accelovance.com
Twitter: @Accelovance